Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men.
Adolescents
Clinical trials
HIV
Human papillomavirus
Men who have sex with men
Vaccine
Journal
Papillomavirus research (Amsterdam, Netherlands)
ISSN: 2405-8521
Titre abrégé: Papillomavirus Res
Pays: Netherlands
ID NLM: 101662552
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
19
07
2018
revised:
06
12
2018
accepted:
10
01
2019
pubmed:
19
1
2019
medline:
11
1
2020
entrez:
19
1
2019
Statut:
ppublish
Résumé
The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18-26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants' mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11-6.42), current smoking (yes vs. no, OR=2.37, 95% CI=1.03-5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95% CI=1.16-10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation. CLINICAL TRIAL NUMBER: NCT01209325.
Identifiants
pubmed: 30658128
pii: S2405-8521(18)30089-2
doi: 10.1016/j.pvr.2019.01.002
pmc: PMC6356116
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT01209325']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
52-61Subventions
Organisme : NCI NIH HHS
ID : P50 CA121974
Pays : United States
Organisme : NICHD NIH HHS
ID : U01 HD040474
Pays : United States
Organisme : NICHD NIH HHS
ID : U01 HD040533
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069536
Pays : United States
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Références
Sex Transm Dis. 2016 Apr;43(4):243-8
pubmed: 26967301
Int J Cancer. 2016 Sep 1;139(5):1098-105
pubmed: 27121353
J Virol. 2015 Oct;89(20):10680-7
pubmed: 26269181
AIDS. 2008 Jun 19;22(10):1203-11
pubmed: 18525266
BMC Infect Dis. 2016 Aug 22;16(1):440
pubmed: 27549219
J Clin Microbiol. 2005 Nov;43(11):5526-35
pubmed: 16272481
J Infect Dis. 2017 Mar 1;215(5):772-780
pubmed: 28011913
Virol J. 2015 Feb 22;12:29
pubmed: 25889023
Vaccine. 2014 Nov 12;32(48):6356-9
pubmed: 25258097
Vaccine. 2009 May 29;27 Suppl 1:A17-23
pubmed: 19480955
MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30
pubmed: 25167164
Lancet Oncol. 2012 May;13(5):487-500
pubmed: 22445259
Head Neck. 2016 Apr;38 Suppl 1:E399-405
pubmed: 25580925
J Adolesc Health. 2010 Apr;46(4 Suppl):S12-9
pubmed: 20307839
Cancer. 2004 Jul 15;101(2):270-80
pubmed: 15241823
J Gen Virol. 2010 Aug;91(Pt 8):2068-2072
pubmed: 20392894
Biomed Res Int. 2017;2017:2641259
pubmed: 28133605
J Infect Dis. 2016 Sep 1;214(5):689-96
pubmed: 27296847
MMWR Morb Mortal Wkly Rep. 2015 Jul 31;64(29):784-92
pubmed: 26225476
Sex Transm Dis. 2015 Dec;42(12):671-6
pubmed: 26562695
J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9
pubmed: 18614927
Br J Health Psychol. 2017 May;22(2):345-361
pubmed: 28191723
Sex Transm Dis. 2017 Mar;44(3):173-180
pubmed: 28178116
J Infect Dis. 1998 Feb;177(2):361-7
pubmed: 9466522
BMC Infect Dis. 2014 Dec 16;14:671
pubmed: 25510243
PLoS One. 2016 Jul 08;11(7):e0158090
pubmed: 27391265
Clin Infect Dis. 2016 Jun 1;62(11):1367-1374
pubmed: 26962079
Lancet Infect Dis. 2018 Feb;18(2):198-206
pubmed: 29158102
J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19662
pubmed: 25397412
PLoS One. 2016 Jul 06;11(7):e0157976
pubmed: 27384050
J Infect Dis. 2002 May 1;185(9):1229-37
pubmed: 12001039
J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):437-43
pubmed: 26379067
J Clin Microbiol. 1997 Jan;35(1):11-9
pubmed: 8968874
Oncogene. 2010 Jun 10;29(23):3435-45
pubmed: 20383192
J Clin Oncol. 2018 Jan 1;36(1):68-75
pubmed: 29140774
MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):300-4
pubmed: 25811679
PLoS One. 2016 Aug 22;11(8):e0161460
pubmed: 27548632
Sex Transm Infect. 2015 Jun;91(4):284-6
pubmed: 25887283
J Infect Dis. 2017 Jun 15;215(12):1832-1835
pubmed: 28505338
PLoS One. 2015 Oct 05;10(10):e0139524
pubmed: 26437318
J Gen Virol. 2005 Oct;86(Pt 10):2709-2720
pubmed: 16186224
PLoS One. 2013 Jul 17;8(7):e68329
pubmed: 23873171
LGBT Health. 2017 Feb;4(1):72-74
pubmed: 27673362
J Virol. 2012 Nov;86(22):12384-96
pubmed: 22951839